Comprehensive Stock Comparison
Compare Mineralys Therapeutics, Inc. (MLYS) vs Vertex Pharmaceuticals Incorporated (VRTX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | MLYS | Beta 0.40 vs VRTX's 0.44 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | MLYS | +220.1% vs VRTX's +3.6% |
| Efficiency (ROA) | VRTX | 14.8% ROA vs MLYS's -28.6%, ROIC 22.8% vs -107.3% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for hypertension and cardiovascular diseases. It generates no revenue currently but aims to monetize its lead candidate lorundrostat — a selective aldosterone synthase inhibitor — through future drug approvals and commercialization. The company's competitive advantage lies in its targeted approach to aldosterone inhibition, which addresses a specific biological pathway in treatment-resistant hypertension.
Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing transformative medicines for serious diseases, with its flagship franchise targeting cystic fibrosis. It generates nearly all its revenue from CF therapies — primarily Trikafta/Kaftrio — while building a pipeline in pain, kidney disease, and type 1 diabetes. Its moat stems from deep scientific expertise in CFTR biology and a dominant, near-monopoly position in the CF treatment market.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
VRTX leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). MLYS leads in 1 (Financial Metrics). 2 tied.
Financial Metrics (TTM)
VRTX and MLYS operate at a comparable scale, with $11.7B and $0 in trailing revenue.
| Metric | MLYSMineralys Therape… | VRTXVertex Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $11.7B |
| EBITDAEarnings before interest/tax | -$184M | $4.2B |
| Net IncomeAfter-tax profit | -$171M | $3.7B |
| Free Cash FlowCash after capex | -$171M | $3.3B |
| Gross MarginGross profit ÷ Revenue | — | +86.3% |
| Operating MarginEBIT ÷ Revenue | — | +34.1% |
| Net MarginNet income ÷ Revenue | — | +31.3% |
| FCF MarginFCF ÷ Revenue | — | +28.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +11.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +54.0% | +4.7% |
Valuation Metrics
| Metric | MLYSMineralys Therape… | VRTXVertex Pharmaceut… |
|---|---|---|
| Market CapShares × price | $2.3B | $126.2B |
| Enterprise ValueMkt cap + debt − cash | $2.2B | $124.8B |
| Trailing P/EPrice ÷ TTM EPS | -7.99x | 32.43x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 25.66x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.91x |
| EV / EBITDAEnterprise value multiple | — | 26.63x |
| Price / SalesMarket cap ÷ Revenue | — | 10.52x |
| Price / BookPrice ÷ Book value/share | 7.43x | 6.87x |
| Price / FCFMarket cap ÷ FCF | — | 39.51x |
Profitability & Efficiency
VRTX delivers a 21.2% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-30 for MLYS. On the Piotroski fundamental quality scale (0–9), VRTX scores 5/9 vs MLYS's 1/9, reflecting solid financial health.
| Metric | MLYSMineralys Therape… | VRTXVertex Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -29.7% | +21.2% |
| ROA (TTM)Return on assets | -28.6% | +14.8% |
| ROICReturn on invested capital | -107.3% | +22.8% |
| ROCEReturn on capital employed | -89.0% | +23.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 5 |
| Debt / EquityFinancial leverage | — | 0.20x |
| Net DebtTotal debt minus cash | -$114M | $3.7B |
| Cash & Equiv.Liquid assets | $114M | $5.1B |
| Total DebtShort + long-term debt | $0 | $3.7B |
| Interest CoverageEBIT ÷ Interest expense | — | 348.55x |
Total Returns (with DRIP)
A $10,000 investment in VRTX five years ago would be worth $23,616 today (with dividends reinvested), compared to $15,868 for MLYS. Over the past 12 months, MLYS leads with a +220.1% total return vs VRTX's +3.6%. The 3-year compound annual growth rate (CAGR) favors VRTX at 19.6% vs MLYS's 18.1% — a key indicator of consistent wealth creation.
| Metric | MLYSMineralys Therape… | VRTXVertex Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -18.1% | +9.9% |
| 1-Year ReturnPast 12 months | +220.1% | +3.6% |
| 3-Year ReturnCumulative with dividends | +64.6% | +71.1% |
| 5-Year ReturnCumulative with dividends | +58.7% | +136.2% |
| 10-Year ReturnCumulative with dividends | +58.7% | +481.2% |
| CAGR (3Y)Annualised 3-year return | +18.1% | +19.6% |
Risk & Volatility
MLYS is the less volatile stock with a 0.40 beta — it tends to amplify market swings less than VRTX's 0.44 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VRTX currently trades 95.6% from its 52-week high vs MLYS's 61.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MLYSMineralys Therape… | VRTXVertex Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.40x | 0.44x |
| 52-Week HighHighest price in past year | $47.65 | $519.68 |
| 52-Week LowLowest price in past year | $8.69 | $362.50 |
| % of 52W HighCurrent price vs 52-week peak | +61.4% | +95.6% |
| RSI (14)Momentum oscillator 0–100 | 43.5 | 54.6 |
| Avg Volume (50D)Average daily shares traded | 1.0M | 1.2M |
Analyst Outlook
Wall Street rates MLYS as "Buy" and VRTX as "Buy". Consensus price targets imply 77.7% upside for MLYS (target: $52) vs 9.7% for VRTX (target: $545).
| Metric | MLYSMineralys Therape… | VRTXVertex Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $52.00 | $545.08 |
| # AnalystsCovering analysts | 8 | 55 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.6% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 23 | Feb 26 | Change |
|---|---|---|---|
| Mineralys Therapeut… (MLYS) | 100 | 167.41 | +67.4% |
| Vertex Pharmaceutic… (VRTX) | 100 | 162.07 | +62.1% |
Vertex Pharmaceutic… (VRTX) returned +136% over 5 years vs Mineralys Therapeut… (MLYS)'s +59%. A $10,000 investment in VRTX 5 years ago would be worth $23,616 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Mineralys Therapeut… (MLYS) | $0.00 | $0.00 | — |
| Vertex Pharmaceutic… (VRTX) | $1.7B | $12.0B | +605.1% |
Vertex Pharmaceuticals Incorporated's revenue grew from $1.7B (2016) to $12.0B (2025) — a 24.2% CAGR.
Chart 3P/E Ratio History — 8 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Vertex Pharmaceutic… (VRTX) | 144.1 | 29.6 | -79.5% |
Vertex Pharmaceuticals Incorporated has traded in a 21x–144x P/E range over 8 years; current trailing P/E is ~32x.
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Mineralys Therapeut… (MLYS) | -0.74 | -3.66 | -394.6% |
| Vertex Pharmaceutic… (VRTX) | -0.46 | 15.32 | +3430.4% |
Vertex Pharmaceuticals Incorporated's EPS grew from $-0.46 (2016) to $15.32 (2025).
Chart 5Free Cash Flow — 5 Years
Mineralys Therapeutics, Inc. generated $-166M FCF in 2024 (-1043% vs 2021). Vertex Pharmaceuticals Incorporated generated $3B FCF in 2025 (+33% vs 2021).
MLYS vs VRTX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MLYS or VRTX a better buy right now?
Vertex Pharmaceuticals Incorporated (VRTX) offers the better valuation at 32.4x trailing P/E (25.7x forward), making it the more compelling value choice. Analysts rate Mineralys Therapeutics, Inc. (MLYS) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MLYS or VRTX?
Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +136.2%, compared to +58.7% for Mineralys Therapeutics, Inc. (MLYS). A $10,000 investment in VRTX five years ago would be worth approximately $24K today (assuming dividends reinvested). Over 10 years, the gap is even starker: VRTX returned +481.2% versus MLYS's +58.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MLYS or VRTX?
By beta (market sensitivity over 5 years), Mineralys Therapeutics, Inc. (MLYS) is the lower-risk stock at 0.40β versus Vertex Pharmaceuticals Incorporated's 0.44β — meaning VRTX is approximately 11% more volatile than MLYS relative to the S&P 500.
04Which has better profit margins — MLYS or VRTX?
Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.9% net margin versus 0.0% for Mineralys Therapeutics, Inc. — meaning it keeps 32.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39.1% versus 0.0% for MLYS. At the gross margin level — before operating expenses — VRTX leads at 86.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is MLYS or VRTX more undervalued right now?
Analyst consensus price targets imply the most upside for MLYS: 77.7% to $52.00.
06Which pays a better dividend — MLYS or VRTX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MLYS or VRTX better for a retirement portfolio?
For long-horizon retirement investors, Vertex Pharmaceuticals Incorporated (VRTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.44), +481.2% 10Y return). Both have compounded well over 10 years (VRTX: +481.2%, MLYS: +58.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MLYS and VRTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.